Answers are grounded in this paper and cite their sources.
Demonstrates improved drug-like properties in preclinical models, suggesting potential for epilepsy treatment.
Strategic deuterium–hydrogen exchange applied to the first-in-class positive allosteric modulators (PAMs) of the glutamate transporter EAAT2/GLT-1, (R)-AS-1 and (R)-AS-7, yielded novel analogues with improved drug-like properties. Specifically, incorporation of deuterium into the pyrrolidine-2,5-dione ring significantly prolonged the elimination half-life and increased both plasma and brain exposure in mice. These enhancements translated into more sustained antiseizure activity and a more favorable pharmacokinetic/pharmacodynamic (PK/PD) relationship. Similar to their nondeuterated counterparts, the new deuterated analogues displayed broad-spectrum antiseizure efficacy across multiple in vivo mouse seizure models, including maximal electroshock (MES), 6 Hz (32/44 mA), acute pentylenetetrazole (PTZ), and PTZ-induced kindling. Among these compounds, d6-(R)-AS-7 demonstrated the most robust antiseizure effects and the most advantageous overall pharmacokinetic profile following both intraperitoneal and oral administration. Mechanistic studies revealed that d6-(R)-AS-7 markedly enhanced glutamate uptake in COS-7 cells expressing EAAT2 as well as in primary astrocyte cultures. Furthermore, electrophysiological recordings in acute mouse hippocampal slices, together with two-electrode voltage-clamp recordings in Xenopus laevis oocytes expressing EAAT2, confirmed increased transporter-mediated currents. Collectively, these findings identify d6-(R)-AS-7 as a potent EAAT2 PAM with improved pharmacokinetic properties and strong antiseizure efficacy, supporting its further development as a therapeutic candidate for epilepsy and other disorders associated with glutamate excitotoxicity.
No takes yet. Share an insight, caveat, or question.
Abram et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: